Licensed COVID-19 vaccines ameliorate viral infection by inducing production of neutralizing antibodies that bind the SARS-CoV-2 Spike protein and inhibit viral cellular entry. However, the clinical effectiveness of these vaccines is transitory as viral variants escape antibody neutralization. Effective vaccines that solely rely upon a T cell response to combat SARS-CoV-2 infection could be transformational because they can utilize highly conserved short pan-variant peptide epitopes, but a mRNA-LNP T cell vaccine …

Abstract T cells mediate immune responses against pathogens and cancer through T cell receptors (TCRs) that recognize foreign peptides presented on the cell surface by Major Histocompatibility Complex (MHC) proteins. TCRs carry enormous diversity and differ across individuals, and mechanisms that determine TCR-pMHC binding are poorly understood. The ability to predict TCR-pMHC interactions would accelerate development of cellular therapeutics to design TCRs that specifically bind to a target of interest. We design…

<p>PDF file - 113K</p>

<p>PDF file - 95K</p>

<div>Abstract<p>The ubiquitin-like SUMO proteins covalently modify protein substrates and regulate their functional properties. In a broad spectrum of cancers, the tumor suppressor PML undergoes ubiquitin-mediated degradation primed by CK2 phosphorylation. Here, we report that the SUMO E3-ligase inhibitor PIAS1 regulates oncogenic signaling through its ability to sumoylate PML and the PML-RARA oncoprotein of acute promyelocytic leukemia (APL). PIAS1-mediated SUMOylation of PML promoted CK2 interaction …